Brochure - Continuous Renal Replacement Therapy (CRRT) Market

HEALTHCARE
CONTINUOUS RENAL
REPLACEMENT THERAPY
(CRRT) MARKET
Global Forecast to 2020
REPORT CODE CONTINUOUS RENAL REPLACEMENT THERAPY (CRRT) MARKET -

MD 3842
GLOBAL FORECAST TO 2020
By Products (System, Disposables (Hemofilters & Bloodlines), & Dialysate/Replacement Fluids),
Modality (SCUF, CVVH, CVVHD, CVVHDF) And Geography
REPORT OVERVIEW
1.1 OBJECTIVES OF THE STUDY

• To define, describe, and forecast the CRRT market on the basis of products and
modalities
• To provide detailed information regarding major factors influencing the growth of
the market (drivers, restraints, opportunities, and industry-specific challenges)
• To strategically analyze micromarkets1 with respect to their individual growth
trends, future prospects, and contributions to the total market
• To analyze opportunities in the market for stakeholders and provide details of the
competitive landscape for market leaders
• To forecast the market size (by value) of individual segments with respect to four
main regions, namely, North America (U.S. and Canada), Europe (Germany,
France, U.K., and Rest of Europe), Asia-Pacific (China, India, Japan, and Rest of
Asia-Pacific), and the Rest of the World
• To strategically profile key players and comprehensively analyze their market
shares and core competencies2
• To track and analyze competitive developments such as new product launches;
agreements, partnerships, and joint ventures; mergers and acquisitions; and
research and development activities in the CRRT market
sales@marketsandmarkets.com www.marketsandmarkets.com 1
INTRODUCTION
1.2 MARKET DEFINITION

• Continuous renal replacement therapy (CRRT) is a dialysis modality used to substitute for impaired renal function
over an extended period, intended to be applied for up to 24 hours a day. This technique is designed to treat
hospitalized and critically ill patients in the intensive care unit who develop acute kidney injury (AKI). Unlike
chronic kidney disease, which occurs slowly over time, AKI often occurs in hospitalized patients treated in an
intensive care environment, and typically occurs over a few hours to a few days. The term Acute Kidney Failure
(ARF) is used to define severe or irreversible AKI that is fatal and requires intensive treatment.
1.3 MARKET SCOPE

• This study covers the market for CRRT products used in the treatment of AKI patients in ICUs to arrive at
the CRRT market size (by product and modality) for 2015 to 2020
• The number of procedures for each region/country has been estimated on the basis of the circuit life of
CRRT in a particular region
• The market size for CRRT services is not covered under the scope of study
• The market size of CRRT products that are used off-label (without regulatory approval) in a few countries is
not considered under the scope of the study
• The market size for the CRRT products used in the treatment of patients other than CRRT is covered under
the scope of the study
• The market for medications used during CRRT treatment is not under the scope of the study
1.3.1 MARKETS COVERED

• This research report categorizes the CRRT market into the following segments:
• Global CRRT Market, by Product
• CRRT Monitors Systems
• CRRT Disposables
• Bloodlines
• Hemofilters
• Other Disposables
• CRRT Dialysate/Replacement Fluids
• Global CRRT market, by Modality
• Slow continuous ultrafiltration (SCUF)
• Continuous venovenous hemofiltration (CVVH)
• Continuous venovenous hemodialysis (CVVHD)
• Continuous venovenous hemodiafiltration (CVVHDF)
INTRODUCTION
• Global CRRT Market, by Region

• North America
• U.S.
• Canada
• Europe
• Germany
• France
• U.K.
• Rest of Europe
• Asia-Pacific
• Japan
• China
• India
• Rest of Asia-Pacific
• Rest of the World
1.3.2 YEARS CONSIDERED FOR THE STUDY

•
1.4 CURRENCY
• The base currency used in the report is USD, with market size indicated in USD million.
• For companies reporting their revenue in U.S. dollars (USD), the revenues were picked up from their annual
report
• For companies that reported their revenues in other currencies, the average annual currency conversion
rate was used for the particular year to convert the value to USD
INTRODUCTION
1.5 LIMITATIONS
•
• However, to overcome the limitations and to maintain the effectiveness of the research work, several strategic
approaches and recommendations of the industry experts were utilized to come up with the research study.
1.6 STAKEHOLDERS
• CRRT Manufacturers, Suppliers, and Distributors
• CRRT Service Providers
• Renal Research Laboratories
• Renal Association and Organizations
• Hospitals and Critical Care Units
• Academic Medical Centers and Universities
• Business Research and Consulting Service Providers
RESEARCH METHODOLOGY
2.1 RESEARCH METHODOLOGY STEPS

• This research study involved the usage of extensive secondary sources, directories, and databases such as
Hoovers, Bloomberg Business, Factiva, and Avention, along with government databases, to identify and collect
information useful for this technology-based, market-oriented, and commercial study of the CRRT market. In-
depth interviews were conducted from various primary respondents that mainly include key industry participants,
subject-matter experts (SMEs), C-level executives of key market players, and industry consultants to obtain and
verify critical qualitative and quantitative information as well as to assess future prospects. The following figures
show the market research methodology applied in making this report on the CRRT market:
• FIGURE 1 GLOBAL CRRT MARKET: RESEARCH METHODOLOGY STEPS

•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
2.2 SECONDARY AND PRIMARY RESEARCH METHODOLOGY
2.2.1 SECONDARY RESEARCH

• The secondary sources referred to for this research study include publications from government sources
(such as the National Institutes of Health (NIH), U.S. FDA, World Bank, WHO); corporate filings (such
as annual reports, SEC filings, investor presentations, and financial statements); research journals; press
releases; and trade, business, and professional associations; among others. Secondary sources were used
to identify and collect useful information for this extensive, technical, and commercial study of the global
CRRT market. Secondary research was mainly used to obtain key information about the industry’s total pool
of key players, market classification, and segmentation according to industry trends to the bottom-most
level, global market trends, and key developments by both public and private organizations in the CRRT
market.
2.2.1.1 KEY DATA FROM SECONDARY SOURCES

•
•
•
•
•
•
•
•
•
•
•
•
•
•
•
• The following non-exclusive list of secondary sources was referred to:

• Associations/Organizations/Institutes:
• Centers for Medicare and Medicaid Services (CMS), The United States Renal Data System (USRDS), American
Society of Nephrology (ASN), The American Association of Kidney Patients (AAKP), The Canadian Society of
Nephrology, International Society of Nephrology (ISN), American Nephrology Nurses’ Association, The Renal
Association, The National Kidney Foundation, International Federation of Kidney Foundations, Critical Care
Canada Forum, World Congress of Nephrology, European Society of Paediatric and Neonatal Intensive Care, The
European Renal Association – European Dialysis and Transplant Association (ERA-EDTA), The Intensive Care
Society, Renal Association, European Society for Paediatric Nephrology, The Asian Pacific Society of Nephrology,
Singapore Society Of Nephrology, Asian Renal Association (ARA), Taiwan Society of Nephrology, Japanese
Society of Nephrology, Chinese Society of Nephrology, Indian Society of Nephrology, Renal Care Society of South
Africa (RCCSA), and Sociedade Brasileira de Nefrologia (SBN), among others.
• The secondary research involved three major activities:
• Background Study
• To build a basic understanding of the CRRT market
• MarketsandMarkets data repository analysis, followed by drawing and updating data tables by using
current information
• Identifying data gaps and key players in each segment
• Market Understanding
• Identifying stakeholders and key decision makers in different regions
• Selection criteria of key decision makers
• Analyzing the competitive landscape
• Major players with their product portfolios
• Strategies adopted by the players to position their products
• Regional/country-wise market analysis
• Trends
• Identifying and analyzing key products and trends to draw notes and include the consideration in the final
forecasts
• Major drivers, restraints, challenges, and opportunities prevailing in the market
• Reimbursement scenario
• Regulatory landscape
• Pricing and cost analysis
2.2.2 PRIMARY RESEARCH

• Extensive primary research was conducted after acquiring knowledge about the CRRT market scenario through
secondary research. More than 40 primary interviews were conducted from both the demand (nephrologists,
intensivists, purchase managers, and administrators of hospitals and head of research universities) and supply
sides (CRRT product manufacturers and distributors). The primaries interviewed for this study include experts
from the CRRT industry, such as CEOs, VPs, directors, sales heads, and marketing managers of the tier 1, 2, and
3 companies engaged in offering CRRT products across the globe; nephrologists, intensivists, ICU and renal
nurses, purchase managers, and administrators of hospitals and heads of research universities. Approximately
62% and 38% primary interviews were conducted from both the demand and supply sides, respectively.
• A robust primary research methodology has been adopted to validate the contents of the report and to fill
gaps
• Telephonic and e-mail communication was adopted to conduct interviews (questionnaires were designed
and sent to primary participants as per their convenience)
• FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION

•
• Note: *Others include sales managers, marketing managers, business development managers, product managers, distributors, and suppliers
Company categorization according to revenue: Tier 1 (Revenue: More than USD 1 billion), Tier 2 (Revenue: USD 1 billion to USD 500 million), and Tier 3 (Revenue: Less than USD 500 million).
2.2.2.1 KEY DATA FROM PRIMARY SOURCES

•


 
 
 

2.2.2.2 KEY INDUSTRY INSIGHTS
• FIGURE 3 SUPPLY SIDE

•
“ “
“ “
Supplier, CRRT Products
“ “
CEO, Key Player in the CRRT Disposable Products Market
Marketing Director, Leading CRRT company
“ “
“ “
Sales Manager, Leading CRRT Company
“ “
Product Manager, Leading CRRT
Company
Senior Scientist, R&D, Leading CRRT Company
• FIGURE 4 DEMAND SIDE

•
“ “
“ “ Senior Nephrologist of a U.S.
“ “
Hospital
Independent Renal Consultant

Intensivist, Leading Kidney Care Hospital (U.K.)
(Germany)
“ “ “ “
Renal Nurse, Leading Canadian
Nephrologist, Hospital (India)
hospital
2.3 MARKET SIZE ESTIMATION METHODOLOGY

• Both, top-down and bottom-up approaches were used to estimate and validate the size of the global market and
to estimate the size of various other dependent submarkets in the overall CRRT market. The research methodology
used to estimate the market size includes the following details:
• The key players in the market were identified through secondary research and their market shares were determined
through primary and secondary research. This entire procedure includes the study of the annual and financial
reports of the top market players and extensive interviews for key insights with industry leaders such as CEOs,
VPs, directors, and marketing executives. All percentage shares, splits, and breakdowns were determined using
secondary sources and verified through primary sources. All possible parameters that affect the markets covered
in this research study have been accounted for, viewed in extensive detail, verified through primary research, and
analyzed to get the final quantitative and qualitative data. This data was consolidated and added with detailed
inputs and analysis from MarketsandMarkets, and presented in this report.
• The following figure shows the overall number of procedures and the market size estimation process employed
for the purpose of this study:
• FIGURE 5 ESTIMATION OF CRRT PROCEDURAL VOLUME

•
• Note: *Procedures are calculated based on epidemiology data gathered from interviews conducted with key nephrologists and intensivists, utilization of CRRT across various regions, and
incidence & prevalence data reported by governments/public organizations
• FIGURE 6 RESEARCH METHODOLOGY: TOP-DOWN APPROACH {FOR MARKET SIZE ESTIMATION OF

DISPOSABLES (BLOODLINE SETS, HEMOFILTERS, AND WATER BAGS)}
•
•
•
•
•
•
•
•
• FIGURE 7 RESEARCH METHODOLOGY: TOP-DOWN APPROACH (FOR MARKET-SIZE ESTIMATION

OF CRRT MACHINES)
•
•
•
•
•
•
•
•
• FIGURE 8 RESEARCH METHODOLOGY: BOTTOM-UP APPROACH

•
•
•
•
•
•
•
• FIGURE 9 RESEARCH DESIGN

•
• •
•
•
• •
•
•
•
•
•
•
2.4 MARKET DATA VALIDATION AND TRIANGULATION

• In order to complete the overall market engineering process and to arrive at the exact statistics for all the market
segments and subsegments, the data triangulation and market validation procedures explained below were
implemented, wherever applicable.
• FIGURE 10 DATA TRIANGULATION STEPS (TOP-DOWN AND BOTTOM-UP APPROACHES)

•
• FIGURE 11 DATA TRIANGULATION METHODOLOGY

•
•
•
•
•
•
•
•
•
•
• •
2.5 ASSUMPTIONS FOR THE STUDY

•
• Note 1: Regionwise inflation/deflation of prices of CRRT products in the next five years has been considered while forecasting the market size.
Note 2: Market values have been rounded off till the second decimal. Due to this, there may be a slight difference in the actual total and the total mentioned in market tables.
TABLE OF CONTENTS
1 INTRODUCTION.........................................................................................................................17
• 1.1 OBJECTIVES OF THE STUDY...........................................................................................................................................16
• 1.2 MARKET DEFINITION.......................................................................................................................................................16
• 1.3 MARKET SCOPE...............................................................................................................................................................16
• 1.3.1 MARKETS COVERED......................................................................................................................................17
• 1.3.2 YEARS CONSIDERED FOR THE STUDY.........................................................................................................18
• 1.4 CURRENCY......................................................................................................................................................................18
• 1.5 LIMITATIONS....................................................................................................................................................................18
• 1.6 STAKEHOLDERS...............................................................................................................................................................19
2 RESEARCH METHODOLOGY.....................................................................................................20
• 2.1 RESEARCH METHODOLOGY STEPS................................................................................................................................20
• 2.2 SECONDARY AND PRIMARY RESEARCH METHODOLOGY.............................................................................................21
• 2.2.1 SECONDARY RESEARCH...............................................................................................................................21
• 2.2.1.1 KEY DATA FROM SECONDARY SOURCES................................................................................21
• 2.2.2 PRIMARY RESEARCH....................................................................................................................................22
• 2.2.2.1 KEY DATA FROM PRIMARY SOURCES.....................................................................................23
• 2.2.2.2 KEY INDUSTRY INSIGHTS........................................................................................................24
• 2.3 MARKET SIZE ESTIMATION METHODOLOGY..................................................................................................................26
• 2.4 MARKET DATA VALIDATION AND TRIANGULATION........................................................................................................29
• 2.5 ASSUMPTIONS FOR THE STUDY....................................................................................................................................31
3 EXECUTIVE SUMMARY..............................................................................................................32
4 PREMIUM INSIGHTS.................................................................................................................37
• 4.1 MARKET POTENTIAL........................................................................................................................................................37
• 4.2 MARKET OPPORTUNITY..................................................................................................................................................38
• 4.3 CRRT MARKET, BY PRODUCT AND MODALITY (2015 VS. 2020)....................................................................................38
• 4.4 CRRT MARKET, BY MODALITY (2015).............................................................................................................................39
• 4.5 CRRT MARKET, BY COUNTRY (2015 VS. 2020)...............................................................................................................40
TABLE OF CONTENTS
5 MARKET OVERVIEW..................................................................................................................41
• 5.1 INTRODUCTION...............................................................................................................................................................41
• 5.2 MARKET SEGMENTATION................................................................................................................................................42
• 5.2.1 BY PRODUCT.................................................................................................................................................42
• 5.2.2 BY MODALITY................................................................................................................................................43
• 5.3 MARKET DYNAMICS........................................................................................................................................................43
• 5.3.1 DRIVERS........................................................................................................................................................44
• 5.3.1.1 INCREASING PREVALENCE OF AKI..........................................................................................44
• 5.3.1.2 RISING ADOPTION OF CRRT FOR THE TREATMENT OF RENAL DISORDERS..........................44
• 5.3.1.3 GROWING NUMBER OF ICU PATIENTS....................................................................................45
• 5.3.1.4 RAPID RISE IN AGING POPULATION........................................................................................45
• 5.3.1.5 CLINICAL ADVANTAGES OF CRRT OVER INTERMITTENT BLOOD PURIFICATION

TECHNIQUES............................................................................................................................46
• 5.3.1.6 CRRT IS A GOLD STANDARD FOR TREATMENT OF HEMODYNAMICALLY UNSTABLE

PATIENTS..................................................................................................................................46
• 5.3.1.7 TECHNOLOGICAL ADVANCEMENTS AND NEW PRODUCT LAUNCHES..................................46
• 5.3.1.8 INCREASING PREVALENCE OF SEPSIS....................................................................................47
• 5.3.2 RESTRAINTS..................................................................................................................................................48
• 5.3.2.1 HIGH COMPLEXITY OF THERAPY............................................................................................48
• 5.3.2.1.1 LACK OF STANDARD TREATMENT GUIDELINES...............................................48
• 5.3.2.1.2 COMPLICATIONS ASSOCIATED WITH CRRT.....................................................49

• 5.3.2.2 HIGH PROCEDURAL COST OF CRRT........................................................................................49
• 5.3.2.3 STRINGENT REGULATORY GUIDELINES FOR CRRT IN NORTH AMERICA...............................50
• 5.3.2.4 DEARTH OF TRAINED ICU NURSES..........................................................................................50
• 5.3.3 OPPORTUNITIES............................................................................................................................................51
• 5.3.3.1 EMERGING MARKETS..............................................................................................................51
• 5.3.3.2 BROADENING APPLICATION HORIZON OF CRRT.....................................................................51
• 5.3.3.2.1 EVOLUTION OF CRRT FROM SIMPLE RENAL REPLACEMENT

TREATMENT TO A MULTI-ORGAN SUPPORT THERAPY (MOST)......................51
• 5.3.3.2.2 CRRT: PROGRESSION FROM ADAPTIVE RENAL DEVICES TO

MULTIPURPOSE TREATMENT MACHINES........................................................52
• 5.3.3.3 ONGOING RESEARCHES TO ESTABLISH SAFETY AND EFFICACY PROFILE OF CRRT............52
TABLE OF CONTENTS
• 5.3.3.4 DEVELOPMENT OF A CRRT SYSTEM FOR PEDIATRIC PATIENTS............................................53
• 5.3.3.4.1 THE CARPEDIEM PROJECT...............................................................................53
• 5.3.3.5 UNTAPPED MARKET GROWTH OPPORTUNITIES IN NORTH AMERICA...................................53
• 5.3.4 CHALLENGES................................................................................................................................................55
• 5.3.4.1 POOR REIMBURSEMENT SCENARIO IN DEVELOPING COUNTRIES........................................55
• 5.3.4.2 LACK OF SUBSTANTIAL CLINICAL EVIDENCES SUPPORTING EFFICACY OF CRRT...............55
• 5.3.4.3 CURRENTLY APPROVED CRRT TECHNOLOGY IS INADEQUATE FOR CHILDREN....................55
• 5.3.4.4 LACK OF AWARENESS ABOUT THE BENEFITS OF CRRT.........................................................55
• 5.3.5 WINNING IMPERATIVES................................................................................................................................56
• 5.3.5.1 SELLING MACHINES ALONG WITH DISPOSABLES TO END USERS.......................................56
• 5.3.5.2 HIGH BARGAINING MARGINS ON DISPOSABLES AS WELL AS MACHINES...........................56
• 5.3.5.3 DEVELOPMENT OF CRRT MACHINE THAT IS ONLY COMPATIBLE WITH RESPECTIVE

COMPANY’S DISPOSABLES.....................................................................................................57
• 5.3.5.4 CORE COMPETENCY OF PLAYERS..........................................................................................57
• 5.3.6 INDUSTRY TRENDS.......................................................................................................................................57
• 5.3.6.1 TRAINING PROGRAMS FOR THE OPERATION OF CRRT DEVICES...........................................57
• 5.3.6.2 RISING ADOPTION OF USER-FRIENDLY CRRT MACHINES.....................................................58
6 INDUSTRY INSIGHTS................................................................................................................59
• 6.1 INTRODUCTION...............................................................................................................................................................59
• 6.2 REIMBURSEMENT SCENARIO.........................................................................................................................................60
• 6.2.1 NORTH AMERICA...........................................................................................................................................60
• 6.2.2 EUROPE.........................................................................................................................................................60
• 6.2.3 ASIA-PACIFIC (EXCLUDING JAPAN).............................................................................................................61
• 6.2.4 JAPAN............................................................................................................................................................62
• 6.2.5 REST OF THE WORLD....................................................................................................................................62
• 6.3 REGULATORY LANDSCAPE.............................................................................................................................................63
• 6.3.1 NORTH AMERICA...........................................................................................................................................63
• 6.3.2 EUROPE.........................................................................................................................................................63
• 6.3.3 ASIA-PACIFIC................................................................................................................................................64
• 6.3.4 REST OF THE WORLD....................................................................................................................................64
TABLE OF CONTENTS
• 6.4 PORTER’S FIVE FORCES ANALYSIS.................................................................................................................................65
• 6.4.1 COMPETITIVE INTENSITY..............................................................................................................................66
• 6.4.2 BARGAINING POWER OF BUYERS.................................................................................................................66
• 6.4.3 BARGAINING POWER OF SUPPLIERS...........................................................................................................66
• 6.4.4 THREAT OF SUBSTITUTES.............................................................................................................................66
• 6.4.5 THREAT OF NEW ENTRANTS.........................................................................................................................66
• 6.5 PRICING AND COST ANALYSIS.......................................................................................................................................67
• 6.6 STRATEGIC RECOMMENDATIONS...................................................................................................................................68
• 6.6.1 DESIGN RECOMMENDATIONS FOR CRRT MACHINES.................................................................................68
• 6.6.2 KEY STRATEGIES FOR PLAYERS SEEKING TO ENTER THE CRRT MARKET..................................................69
7 ADOPTION OF CRRT, BY REGION..............................................................................................70

• 7.1 INTRODUCTION...............................................................................................................................................................70
• 7.2 UTILIZATION OF CRRT PROCEDURES, BY REGION.........................................................................................................70
• 7.3 NUMBER OF CRRT PATIENTS, BY REGION......................................................................................................................73
8 CRRT MARKET, BY PRODUCT...................................................................................................74

• 8.1 INTRODUCTION...............................................................................................................................................................75
• 8.1.1 DIALYSATE AND REPLACEMENT FLUIDS.....................................................................................................76
• 8.1.2 CRRT DISPOSABLES.....................................................................................................................................78
• 8.1.2.1 HEMOFILTERS..........................................................................................................................81
• 8.1.2.2 BLOODLINE SETS (TUBING SETS)...........................................................................................81
• 8.1.2.3 OTHER DISPOSABLES..............................................................................................................82
• 8.1.3 CRRT SYSTEMS.............................................................................................................................................82
9 CRRT MARKET, BY MODALITY..................................................................................................85

• 9.1 INTRODUCTION...............................................................................................................................................................86
• 9.2 CONTINUOUS VENOVENOUS HEMOFILTRATION (CVVH)...............................................................................................87
• 9.3 CONTINUOUS VENOVENOUS HEMODIAFILTRATION (CVVHDF).....................................................................................89
• 9.4 CONTINUOUS VENOVENOUS HEMODIALYSIS (CVVHD)................................................................................................92
• 9.5 SLOW-CONTINUOUS ULTRAFILTRATION (SCUF)............................................................................................................94
TABLE OF CONTENTS
10 CRRT MARKET, BY REGION......................................................................................................96

• 10.1 INTRODUCTION...............................................................................................................................................................97
• 10.2 CRRT MARKET, BY REGION.............................................................................................................................................99
• 10.2.1 EUROPE.........................................................................................................................................................99
• 10.2.1.1 CRRT MACHINES APPROVED FOR MULTIPLE APPLICATIONS.............................................101
• 10.2.1.2 INTENSIVISTS’ PREFERENCE FOR CRRT FOR AKI TREATMENT............................................101
• 10.2.1.3 PLAYERS FOCUS ON LEVERAGING GROWTH OPPORTUNITIES IN EUROPE.........................101
• 10.2.1.4 GERMANY...............................................................................................................................104
• 10.2.1.4.1 RISING FOCUS OF PLAYERS ON THE GERMAN CRRT MARKET.....................104
• 10.2.1.5 U.K..........................................................................................................................................105
• 10.2.1.5.1 RISING AWARENESS ABOUT AKI IN U.K.........................................................105
• 10.2.1.6 FRANCE..................................................................................................................................106
• 10.2.1.6.1 SYMPOSIA AND CONFERENCES.....................................................................106
• 10.2.1.7 REST OF EUROPE...................................................................................................................108
• 10.2.1.7.1 CLINICAL RESEARCH AND TRIALS DRIVING MARKET GROWTH

IN ROE..............................................................................................................108
• 10.2.2 NORTH AMERICA.........................................................................................................................................109
• 10.2.2.1 NORTH AMERICAN UTILIZATION OF CRRT LOWER THAN THAT OF EUROPE,

AUSTRALIA, AND JAPAN........................................................................................................111
• 10.2.2.2 REGULATORY POLICIES, A KEY HINDRANCE TO MARKET GROWTH....................................112
• 10.2.2.3 U.S..........................................................................................................................................113
• 10.2.2.3.1 PREVALENCE OF AKI, ESRD RISING DUE TO GROWTH IN AGING

POPULATION....................................................................................................113
• 10.2.2.3.2 TECHNOLOGICAL ADVANCEMENT TO BOOST DEMAND FOR

CRRT PRODUCTS............................................................................................114
• 10.2.2.3.3 ONGOING CLINICAL TRIALS TO PROVE SAFETY AND EFFICACY

OF CRRT PRODUCTS.......................................................................................114
• 10.2.2.3.4 GOVERNMENT FUNDING & GRANTS TO DEVELOP COST-EFFECTIVE

TREATMENTS FOR AKI PATIENTS....................................................................114
• 10.2.2.3.5 SHORTAGE OF REGISTERED NURSES IN ICU SETTINGS................................115
• 10.2.2.4 CANADA.................................................................................................................................116
• 10.2.2.4.1 RISING AKI PREVALENCE................................................................................116
• 10.2.2.4.2 BARRIERS TO ENTER THE CANADIAN CRRT MARKET....................................116
TABLE OF CONTENTS
• 10.2.2.4.3 HIGH COSTS OF CRRT AS COMPARED TO IHD..............................................117
• 10.2.3 ASIA-PACIFIC..............................................................................................................................................118
• 10.2.3.1 HIGH USE OF CRRT IN AUSTRALIA AND JAPAN....................................................................118
• 10.2.3.2 STUDIES AND CLINICAL TRIALS TO ESTABLISH THE SAFETY AND

EFFICACY PROFILE OF CRRT.................................................................................................120
• 10.2.3.3 DEARTH OF REIMBURSEMENT AND TECHNICAL EXPERTISE...............................................120
• 10.2.3.4 JAPAN.....................................................................................................................................122
• 10.2.3.4.1 JAPAN FOCUSING ON THE USE OF CRRT FOR NON-RENAL INDICATIONS...............122
• 10.2.3.4.2 LARGE NUMBER OF DOMESTIC MANUFACTURERS - A BARRIER TO

THE ENTRY OF MAJOR PLAYERS....................................................................123
• 10.2.3.5 CHINA.....................................................................................................................................124
• 10.2.3.5.1 RISING INCIDENCE OF AKI AND ESRD IN THE CHINA....................................124
• 10.2.3.6 INDIA.......................................................................................................................................125
• 10.2.3.7 REST OF ASIA-PACIFIC..........................................................................................................127
• 10.2.3.7.1 HIGH UTILIZATION OF CRRT IN AUSTRALIA...................................................127
• 10.2.4 REST OF THE WORLD (ROW)......................................................................................................................129
• 10.2.4.1 SOUTH AFRICA.......................................................................................................................129
• 10.2.4.2 LATIN AMERICA AND THE MIDDLE EAST..............................................................................129
11 COMPETITIVE INTELLIGENCE ANALYSIS................................................................................131

• 11.1 COMPETITIVE INTENSITY..............................................................................................................................................131
• 11.1.1 EVALUATION PARAMETERS AND SCORES.................................................................................................131
• 11.1.2 SCORING METHODOLOGY..........................................................................................................................132
• 11.1.3 COMPETITIVE INTENSITY SCORE, BY COMPANY......................................................................................132
• 11.1.3.1 BAXTER INTERNATIONAL INC................................................................................................132
• 11.1.3.2 NXSTAGE MEDICAL, INC........................................................................................................133
• 11.1.3.3 B. BRAUN MELSUNGEN AG...................................................................................................134
• 11.1.3.4 FRESENIUS MEDICAL CARE AG & CO. KGAA........................................................................135
• 11.1.4 COMPETITIVE INTENSITY - MAPPING OF BAXTER, NXSTAGE, B.BRAUN, AND FRESENIUS.....................136
• 11.1.5 MARKET SHARE ANALYSIS.........................................................................................................................137
• 11.1.5.1 BAXTER INTERNATIONAL INC................................................................................................137
• 11.1.5.2 FRESENIUS MEDICAL CARE AG & CO. KGAA........................................................................138
TABLE OF CONTENTS
• 11.1.5.3 NXSTAGE MEDICAL, INC........................................................................................................138
• 11.2 COMPETITIVE SITUATION AND TRENDS.......................................................................................................................139
• 11.2.1 PRODUCT APPROVALS, LAUNCHES, AND ENHANCEMENTS....................................................................140
• 11.2.2 EXPANSIONS...............................................................................................................................................140
• 11.2.3 ACQUISITIONS.............................................................................................................................................142
• 11.2.4 AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS..........................................................................143
12 COMPANY PROFILES...............................................................................................................144
• 12.1 INTRODUCTION.............................................................................................................................................................144
• (Company at a Glance, Recent Financials, Products & Services, Strategies & Insights, & Recent Developments)*
• 12.2 BAXTER INTERNATIONAL INC........................................................................................................................................145
• 12.3 FRESENIUS MEDICAL CARE AG & CO. KGAA...............................................................................................................148
• 12.4 NIKKISO CO., LTD..........................................................................................................................................................151
• 12.5 B. BRAUN MELSUNGEN AG...........................................................................................................................................153
• 12.6 NXSTAGE MEDICAL, INC...............................................................................................................................................155
• 12.7 ASAHI KASEI MEDICAL CO., LTD. (A SUBSIDIARY OF ASAHI KASEI CORPORATION).................................................157
• 12.8 BELLCO S.R.L................................................................................................................................................................159
• 12.9 INFOMED SA..................................................................................................................................................................160
• 12.10 MEDICA S.P.A................................................................................................................................................................161
• 12.11 MEDICAL COMPONENTS, INC......................................................................................................................................162
• 12.12 TORAY MEDICAL COMPANY LIMITED..........................................................................................................................163

• *Details on company at a glance, recent financials, products & services, strategies & insights, & recent developments might not be captured in case of unlisted companies.
13 APPENDIX................................................................................................................................165
• 13.1 INSIGHTS OF INDUSTRY EXPERTS...............................................................................................................................165
• 13.2 DISCUSSION GUIDE......................................................................................................................................................166
• 13.3 INTRODUCING RT: REAL-TIME MARKET INTELLIGENCE..............................................................................................170
• 13.4 AVAILABLE CUSTOMIZATIONS......................................................................................................................................171
• 13.5 RELATED REPORTS........................................................................................................................................................172
LIST OF TABLES
• TABLE 1 USE OF CRRT AS A GOLD STANDARD FOR TREATMENT OF HEMODYNAMICALLY UNSTABLE

PATIENTS IS DRIVING MARKET GROWTH.........................................................................................................48
• TABLE 2 HIGH PROCEDURAL COST OF CRRT RESTRAINING THE MARKET GROWTH...................................................50
• TABLE 3 EVOLUTION OF CRRT FROM SIMPLE RENAL REPLACEMENT TREATMENT TO MULTIPURPOSE

THERAPY UNFOLDS NEW GROWTH OPPORTUNITIES.....................................................................................54
• TABLE 4 LACK OF SUBSTANTIAL CLINICAL EVIDENCES SUPPORTING EFFICACY OF CRRT POSES

A KEY CHALLENGE FOR THE MARKET..............................................................................................................56
• TABLE 5 AVERAGE SELLING PRICE (ASP) OF CRRT MACHINES, BY MANUFACTURER, 2014.......................................67
• TABLE 6 AVERAGE SELLING PRICE OF CRRT BLOODLINES AND DIALYSATE BAGS, 2014............................................68
• TABLE 7 CRRT MARKET SIZE, BY PRODUCT, 2013-2020 (USD MILLION)......................................................................76
• TABLE 8 CRRT DIALYSATE & REPLACEMENT FLUIDS MARKET SIZE, BY REGION,2013-2020 (USD MILLION)............................77
• TABLE 9 EUROPE: CRRT DIALYSATE & REPLACEMENT FLUIDS MARKET SIZE, BY COUNTRY,
2013-2020 (USD MILLION)...............................................................................................................................77
• TABLE 10 NORTH AMERICA: CRRT DIALYSATE & REPLACEMENT FLUIDS MARKET SIZE,
BY COUNTRY, 2013-2020 (USD MILLION)........................................................................................................78
• TABLE 11 ASIA-PACIFIC: CRRT DIALYSATE & REPLACEMENT FLUIDS MARKET SIZE,

BY COUNTRY, 2013-2020 (USD MILLION)........................................................................................................78
• TABLE 12 CRRT MARKET SIZE, BY DISPOSABLES, 2013-2020 (USD MILLION)..............................................................79
• TABLE 13 CRRT DISPOSABLES MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)................................................79
• TABLE 14 EUROPE: CRRT DISPOSABLES MARKET SIZE, BY COUNTRY,2013-2020 (USD MILLION)...............................80
• TABLE 15 NORTH AMERICA: CRRT DISPOSABLES MARKET SIZE, BY COUNTRY,2013-2020 (USD MILLION)................................80
• TABLE 16 ASIA-PACIFIC: CRRT DISPOSABLES MARKET SIZE, BY COUNTRY,2013-2020 (USD MILLION)......................81
• TABLE 17 CRRT SYSTEMS MARKET SIZE, BY REGION, 2013-2020 (USD MILLION)........................................................83
• TABLE 18 EUROPE: CRRT SYSTEMS MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION).....................................83
• TABLE 19 NORTH AMERICA: CRRT SYSTEMS MARKET SIZE, BY COUNTRY,2013-2020 (USD MILLION).......................84
• TABLE 20 ASIA-PACIFIC: CRRT SYSTEMS MARKET SIZE, BY COUNTRY,2013-2020 (USD MILLION).............................84
• TABLE 21 CRRT MARKET SIZE, BY MODALITY, 2013-2020 (USD MILLION)....................................................................87
• TABLE 22 CRRT MARKET SIZE FOR CVVH, BY REGION, 2013-2020 (USD MILLION).......................................................88
• TABLE 23 NORTH AMERICA: CRRT MARKET SIZE FOR CVVH, BY COUNTRY,2013-2020 (USD MILLION)......................88
• TABLE 24 EUROPE: CRRT MARKET SIZE FOR CVVH, BY COUNTRY, 2013-2020 (USD MILLION)....................................89
• TABLE 25 ASIA-PACIFIC: CRRT MARKET SIZE FOR CVVH, BY COUNTRY,2013-2020 (USD MILLION)............................89
• TABLE 26 CRRT MARKET SIZE FOR CVVHDF, BY REGION, 2013-2020 (USD MILLION)...................................................90
• TABLE 27 NORTH AMERICA: CRRT MARKET SIZE FOR CVVHDF, BY COUNTRY,2013-2020 (USD MILLION)..................91
LIST OF TABLES
• TABLE 28 EUROPE: CRRT MARKET SIZE FOR CVVHDF, BY COUNTRY,2013-2020 (USD MILLION).................................91
• TABLE 29 ASIA-PACIFIC: CRRT MARKET SIZE FOR CVVHDF, BY COUNTRY,2013-2020 (USD MILLION)........................91
• TABLE 30 CRRT MARKET SIZE FOR CVVHD, BY REGION, 2013-2020 (USD MILLION)....................................................92
• TABLE 31 NORTH AMERICA: CRRT MARKET SIZE FOR CVVHD, BY COUNTRY,2013-2020 (USD MILLION)....................93
• TABLE 32 EUROPE: CRRT MARKET SIZE FOR CVVHD, BY COUNTRY,2013-2020 (USD MILLION)..................................93
• TABLE 33 ASIA-PACIFIC: CRRT MARKET SIZE FOR CVVHD, BY COUNTRY, 2013-2020 (USD MILLION)........................93
• TABLE 34 CRRT MARKET SIZE FOR SCUF, BY REGION, 2013-2020 (USD MILLION).......................................................94
• TABLE 35 NORTH AMERICA: CRRT MARKET SIZE FOR SCUF, BY COUNTRY, 2013-2020 (USD MILLION)......................94
• TABLE 36 EUROPE: CRRT MARKET SIZE FOR SCUF, BY COUNTRY, 2013-2020 (USD MILLION).....................................95
• TABLE 37 ASIA-PACIFIC: CRRT MARKET SIZE FOR SCUF, BY COUNTRY,2013-2020 (USD MILLION).............................95
• TABLE 38 CRRT MARKET SIZE, BY REGION, 2013-2020 (USD MILLION).........................................................................98
• TABLE 39 EUROPE: CRRT MARKET SIZE, BY PRODUCT, 2013-2020 (USD MILLION)....................................................102
• TABLE 40 EUROPE: CRRT PRODUCTS MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION)................................102
• TABLE 41 EUROPE: CRRT MARKET SIZE, BY MODALITY, 2013-2020 (USD MILLION)...................................................103
• TABLE 42 EUROPE: CRRT MODALITIES MARKET SIZE, BY COUNTRY,2013-2020 (USD MILLION)...............................103
• TABLE 43 GERMANY: CRRT MARKET SIZE, BY PRODUCT, 2013-2020 (USD MILLION).................................................104
• TABLE 44 GERMANY: CRRT MARKET SIZE, BY MODALITY, 2013-2020 (USD MILLION)................................................105
• TABLE 45 U.K.: CRRT MARKET SIZE, BY PRODUCT, 2013-2020 (USD MILLION)...........................................................106
• TABLE 46 U.K.: CRRT MARKET SIZE, BY MODALITY, 2013-2020 (USD MILLION)..........................................................106
• TABLE 47 FRANCE: CRRT MARKET SIZE, BY PRODUCT, 2013-2020 (USD MILLION)....................................................107
• TABLE 48 FRANCE: CRRT MARKET SIZE, BY MODALITY, 2013-2020 (USD MILLION)...................................................107
• TABLE 49 REST OF EUROPE: CRRT MARKET SIZE, BY PRODUCT, 2013-2020 (USD MILLION).....................................109
• TABLE 50 REST OF EUROPE: CRRT MARKET SIZE, BY MODALITY, 2013-2020 (USD MILLION)....................................109
• TABLE 51 NORTH AMERICA: CRRT MARKET SIZE, BY PRODUCT, 2013-2020 (USD MILLION).....................................112
• TABLE 52 NORTH AMERICA: CRRT PRODUCTS MARKET SIZE, BY COUNTRY,2013-2020 (USD MILLION)...................112
• TABLE 53 NORTH AMERICA: CRRT MARKET SIZE, BY MODALITY, 2013-2020 (USD MILLION)....................................113
• TABLE 54 NORTH AMERICA: CRRT MODALITIES MARKET SIZE, BY COUNTRY,2013-2020 (USD MILLION).................113
• TABLE 55 U.S.: CRRT MARKET SIZE, BY PRODUCT, 2013-2020 (USD MILLION)...........................................................115
• TABLE 56 U.S.: CRRT MARKET SIZE, BY MODALITY, 2013-2020 (USD MILLION)..........................................................115
• TABLE 57 CANADA: CRRT MARKET SIZE, BY PRODUCT, 2013-2020 (USD MILLION)...................................................117
LIST OF TABLES
• TABLE 58 CANADA: CRRT MARKET SIZE, BY MODALITY, 2013-2020 (USD MILLION)..................................................117
• TABLE 59 ASIA-PACIFIC: CRRT MARKET SIZE, BY PRODUCT, 2013-2020 (USD MILLION)...........................................120
• TABLE 60 ASIA-PACIFIC: CRRT MARKET SIZE FOR PRODUCTS, BY COUNTRY, 2013-2020 (USD MILLION)...............................121
• TABLE 61 ASIA-PACIFIC: CRRT MARKET SIZE, BY MODALITY, 2013-2020 (USD MILLION)..........................................121
• TABLE 62 ASIA-PACIFIC: CRRT MODALITIES MARKET SIZE, BY COUNTRY, 2013-2020 (USD MILLION).....................121
• TABLE 63 JAPAN: CRRT MARKET SIZE, BY PRODUCT, 2013-2020 (USD MILLION).......................................................123
• TABLE 64 JAPAN: CRRT MARKET SIZE, BY MODALITY, 2013-2020 (USD MILLION)......................................................124
• TABLE 65 CHINA: CRRT MARKET SIZE, BY PRODUCT, 2013-2020 (USD MILLION).......................................................125
• TABLE 66 CHINA: CRRT MARKET SIZE, BY MODALITY, 2013-2020 (USD MILLION)......................................................125
• TABLE 67 INDIA: CRRT MARKET SIZE, BY PRODUCT, 2013-2020 (USD MILLION)........................................................126
• TABLE 68 INDIA: CRRT MARKET SIZE, BY MODALITY, 2013-2020 (USD MILLION).......................................................127
• TABLE 69 REST OF ASIA-PACIFIC: CRRT MARKET SIZE, BY PRODUCT, 2013-2020 (USD MILLION)............................128
• TABLE 70 REST OF ASIA-PACIFIC: CRRT MARKET SIZE, BY MODALITY, 2013-2020 (USD MILLION)...........................129
• TABLE 71 ROW: CRRT MARKET SIZE, BY PRODUCT, 2013-2020 (USD MILLION)..........................................................130
• TABLE 72 ROW: CRRT MARKET SIZE, BY MODALITY, 2013-2020 (USD MILLION)........................................................130
• TABLE 73 PRODUCT APPROVALS, LAUNCHES, AND ENHANCEMENTS, 2012-2015.....................................................140
• TABLE 74 EXPANSIONS, 2012-2015................................................................................................................................140
• TABLE 75 ACQUISITIONS, 2012-2015.............................................................................................................................142
• TABLE 76 AGREEMENTS, PARTNERSHIPS, AND COLLABORATIONS, 2012-2015..........................................................143
LIST OF FIGURES
• FIGURE 1 GLOBAL CRRT MARKET: RESEARCH METHODOLOGY STEPS.........................................................................20
• FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION,AND REGION........................23
• FIGURE 3 SUPPLY SIDE.....................................................................................................................................................24
• FIGURE 4 DEMAND SIDE...................................................................................................................................................25
• FIGURE 5 ESTIMATION OF CRRT PROCEDURAL VOLUME...............................................................................................26
• FIGURE 6 RESEARCH METHODOLOGY: TOP-DOWN APPROACH {FOR MARKET SIZE ESTIMATION

OF DISPOSABLES (BLOODLINE SETS, HEMOFILTERS, AND WATER BAGS)}...................................................27
• FIGURE 7 RESEARCH METHODOLOGY: TOP-DOWN APPROACH (FOR MARKET-SIZE ESTIMATION OF

CRRT MACHINES).............................................................................................................................................27
• FIGURE 8 RESEARCH METHODOLOGY: BOTTOM-UP APPROACH...................................................................................28
• FIGURE 9 RESEARCH DESIGN...........................................................................................................................................28
• FIGURE 10 DATA TRIANGULATION STEPS (TOP-DOWN AND BOTTOM-UP APPROACHES)..............................................29
• FIGURE 11 DATA TRIANGULATION METHODOLOGY...........................................................................................................30
• FIGURE 12 CRRT MARKET SEGMENTATION........................................................................................................................32
• FIGURE 13 EUROPE TO COMMAND THE LARGEST SHARE OF THE OVERALL CRRT MARKETIN 2015.............................33
• FIGURE 14 HEMOFILTERS TO FORM THE LARGEST SEGMENT OF CRRT DISPOSABLES MARKET IN 2015.....................33
• FIGURE 15 CVVHDF IS POISED TO BE THE FASTEST-GROWING SEGMENT DURING 2015-2020.....................................34
• FIGURE 16 ASIA-PACIFIC IS POISED TO GROW AT THE HIGHEST GROWTH RATE IN THE FORECAST PERIOD...............................35
• FIGURE 17 BAXTER WILL CONTINUE TO DOMINATE THE GLOBAL CRRT MARKET DURING FORECAST PERIOD............................36
• FIGURE 18 HIGH POTENTIAL AND APPLICATIONS OF CRRT TO INCREASE ITS SHARE IN THE HIGH-
MARGIN AKI MARKET........................................................................................................................................37
• FIGURE 19 MARKET GROWTH WILL BE DRIVEN BY THE RISING PREVALENCE OF AKI....................................................38
• FIGURE 20 DIALYSATE & REPLACEMENT FLUIDS PRODUCT SEGMENT AND CVVH MODALITY
SEGMENT WILL DOMINATE THE CRRT MARKET..............................................................................................38
• FIGURE 21 CVVH DOMINATES THE ASIA-PACIFIC CRRT MARKET IN 2015.......................................................................39
• FIGURE 22 U.S. TO DOMINATE GLOBAL CRRT MARKET IN THE NEXT FIVE YEARS..........................................................40
• FIGURE 23 CRRT MARKET SEGMENTATION........................................................................................................................42
• FIGURE 24 CRRT MARKET SEGMENTATION, BY PRODUCT................................................................................................42
• FIGURE 25 CRRT MARKET SEGMENTATION, BY MODALITY..............................................................................................43
• FIGURE 26 CRRT MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES..............................................43
• FIGURE 27 CRRT MARKET IS EXPECTED TO GROW INLINE WITH RISING PREVALENCE OF AKI......................................44
LIST OF FIGURES
• FIGURE 28 RISE IN GLOBAL ADOPTION OF CRRT FOR THE TREATMENT OF AKI..............................................................45
• FIGURE 29 KEY FACTORS AFFECTING REIMBURSEMENT RATES FOR CRRT PROCEDURES............................................59
• FIGURE 30 REIMBURSEMENT SCENARIO OF CRRT IN 2015..............................................................................................60
• FIGURE 31 REIMBURSEMENT STRUCTURES VARY WIDELY ACROSS EUROPE.................................................................61
• FIGURE 32 KEY REGULATORY BODIES INVOLVED IN THE APPROVAL OF NEW CRRT PRODUCTS...................................63
• FIGURE 33 PORTER’S FIVE FORCES ANALYSIS – GLOBAL CRRT MARKET........................................................................65
• FIGURE 34 DESIGN RECOMMENDATIONS FOR CRRT MACHINES.....................................................................................68
• FIGURE 35 UTILIZATION OF CRRT AND DIALYSIS FOR THE TREATMENT OF RENAL PATIENTS
IN ICU, BY REGION (2014).................................................................................................................................71
• FIGURE 36 RATE OF SWITCHING FROM CRRT TO IHD, BY REGION, 2014.........................................................................72
• FIGURE 37 NUMBER OF CRRT PATIENTS ACROSS THE GLOBE, 2014...............................................................................73
• FIGURE 38 EUROPE WILL DOMINATE THE OVERALL CRRT MARKET (2015 VS. 2020)......................................................75
• FIGURE 39 DISPOSABLES FORM THE FASTEST-GROWING BUSINESS WITHIN THE GLOBAL CRRT INDUSTRY..............76
• FIGURE 40 HEMOFILTERS TO DOMINATE THE CRRT DISPOSABLES MARKET DURING FORECAST PERIOD....................79
• FIGURE 41 TYPES OF CRRT MODALITIES...........................................................................................................................86
• FIGURE 42 CVVHDF SEGMENT TO GROW AT THE HIGHEST CAGR IN THE FORECAST PERIOD.......................................86
• FIGURE 43 EUROPE TO DOMINATE THE OVERALL CVVH MARKET DURING FORECAST PERIOD.....................................87
• FIGURE 44 EUROPE IS ESTIMATED TO ACCOUNT FOR THE MAJOR SHARE OF THE TOTAL CVVHDF MARKET IN 2015....................90
• FIGURE 45 GROWTH IN AKI CASES WORLDWIDE (2010 -2020)........................................................................................97
• FIGURE 46 EUROPE WILL DOMINATE THE OVERALL CRRT MARKET IN THE FORECAST PERIOD....................................98
• FIGURE 47 THE U.S. WILL BE THE MAJOR CONTRIBUTOR TO THE GLOBAL CRRT MARKET IN
THE FORECAST PERIOD....................................................................................................................................99
• FIGURE 48 EUROPEAN CRRT MARKET SNAPSHOT: GERMANY WILL CONTINUE TO DOMINATE

THE MARKET IN THE FORECAST PERIOD.......................................................................................................100
• FIGURE 49 GERMANY TO DRIVE THE GROWTH OF CRRT MARKET IN EUROPE..............................................................102
• FIGURE 50 CVVH ACCOUNTED FOR THE MAJOR SHARE OF THE EUROPEAN CRRT MARKETIN 2015...........................103
• FIGURE 51 NORTH AMERICAN CRRT MARKET SNAPSHOT: U.S. WILL BE THE MAJOR CONTRIBUTOR TO
MARKET GROWTH IN THE FORECAST PERIOD...............................................................................................111
• FIGURE 52 ASIA-PACIFIC CRRT MARKET SNAPSHOT: CHINA WILL BE THE FASTEST-GROWING COUNTRY
IN THE REGION................................................................................................................................................119
• FIGURE 53 CHINA WILL BE THE FASTEST-GROWING COUNTRY IN THE ASIA-PACIFIC CRRT MARKET
IN THE FORECAST PERIOD..............................................................................................................................122
LIST OF FIGURES
• FIGURE 54 DIALYSATE & REPLACEMENT FLUIDS SEGMENT ACCOUNTS FOR THE MAJOR SHARE OF
THE ROW CRRT MARKET, BY PRODUCT, IN 2015...........................................................................................128
• FIGURE 55 SCORING METHODOLOGY..............................................................................................................................132
• FIGURE 56 COMPARISON OF COMPETITIVE INTENSITY SCORES: BAXTER, NXSTAGE,B.BRAUN, AND FRESENIUS.........................136
• FIGURE 57 RELATIVE POSITIONING OF COMPANIES BASED ON COMPETITIVE INTENSITY SCORE

AND CRRT FOCUS...........................................................................................................................................136
• FIGURE 58 GLOBAL CRRT PRODUCTS MARKET SHARE ANALYSIS, BY KEY PLAYER, 2014...........................................137
• FIGURE 59 GEOGRAPHICAL PRESENCE OF KEY PLAYERS IN CRRT MARKET, 2014........................................................144
• FIGURE 60 BAXTER INTERNATIONAL INC.: COMPANY SNAPSHOT.................................................................................145
• FIGURE 61 FRESENIUS MEDICAL CARE AG & CO. KGAA: COMPANY SNAPSHOT..........................................................148
• FIGURE 62 NIKKISO CO., LTD.: COMPANY SNAPSHOT....................................................................................................151
• FIGURE 63 B. BRAUN MELSUNGEN AG: COMPANY SNAPSHOT......................................................................................153
• FIGURE 64 NXSTAGE MEDICAL, INC.: COMPANY SNAPSHOT.........................................................................................155
• FIGURE 65 ASAHI KASEI CORPORATION: COMPANY SNAPSHOT....................................................................................157
• FIGURE 66 TORAY GROUP: COMPANY SNAPSHOT..........................................................................................................163
SAMPLE TABLES
TABLE 1 NORTH AMERICA: CRRT MODALITIES MARKET SIZE, BY COUNTRY,

2013-2020 (USD MILLION)
CAGR
COUNTRY 2013 2014 2015-e 2020-p
(2015-2020)
U.S. xx.x xx.x xx.x xx.x xx.x%

Canada xx.x xx.x xx.x xx.x xx.x%
TOTAL xx.x xx.x xx.x xx.x xx.%
Source: Acute Kidney Injury Network (AKIN), American Society of Nephrology (ASN), Asian Renal Association, Canadian Society of Nephrology (CSN), ClinicalTrial.gov, Centers for Medicare and Medicaid
Services (CMS), European Societies of Nephrology [ERA-EDTA], FDA, National Kidney Foundation, The United States Renal Data System (USRDS), Annual Reports, SEC Filings, Press Releases, Investor
Presentations, Journals, Expert Interviews, and MarketsandMarkets Analysis
TABLE 2 REST OF ASIA-PACIFIC: CRRT MARKET SIZE, BY PRODUCT,

2013-2020 (USD MILLION)
CAGR
PRODUCT 2013 2014 2015-e 2020-p
(2015-2020)
Dialysate & Replacement Fluids xx.x xx.x xx.x xx.x xx.x%

CRRT Disposables xx.x xx.x xx.x xx.x xx.x%
CRRT Systems xx.x xx.x xx.x xx.x xx.x%
TABLE 3 ROW: CRRT MARKET SIZE, BY MODALITY, 2013-2020 (USD MILLION)
CAGR
MODALITY 2013 2014 2015-e 2020-p
(2015-2020)
CVVH xx.x xx.x xx.x xx.x xx.x%

CVVHDF xx.x xx.x xx.x xx.x xx.x%
SCUF xx.x xx.x xx.x xx.x xx.x%
CVVHD xx.x xx.x xx.x xx.x xx.x%
RELATED REPORTS
RELATED REPORTS
SR. NO. REPORT TITLE PUBLISHED DATE
DIALYSIS MARKET
[(Hemodialysis - Machine, Dialyzer, Bloodlines, Concentrates, Services), November
1 (Peritoneal Dialysis - Cycler, Catheter, Dialysate, CCPD, CAPD, IPD), (End
Users - Hospital, Independent Dialysis Center, Home Dialysis)] – Global 2013
Forecast to 2018
APHERESIS MARKET
by Application (Plasmapheresis, Plateletpheresis, Erythrocytapheresis, September
2 Leukapheresis, and Photopheresis), Procedure (Therapeutic Apheresis,
Donor Apheresis/Apheresis Blood Donation), Technology & by Product - 2015
Global Forecast to 2020
ABOUT MNM
MarketsandMarkets is a global market research and consulting company based in the U.S. It is World’s No. 2 in terms of
premium market research studies published annually. Serving as a business intelligence partner to Fortune 500 companies
across the world, it provides multi-client reports, company profiles, databases, and custom research services.
MarketsandMarkets covers seventeen industry verticals, including advanced materials, aerospace and defense, agriculture,
automotive and transportation, biotechnology, building and construction, chemicals, energy and power, food and beverages,
industrial automation, medical devices, mining, minerals and metals, packaging, pharmaceuticals, semiconductor and
electronics, and telecommunications and IT.
Copyright © 2015 MarketsandMarkets

All Rights Reserved. This document contains highly confidential information and is the sole property of MarketsandMarkets.
No part of it may be circulated, copied, quoted, or otherwise reproduced without the approval of MarketsandMarkets.
DISCLAIMER:
MarketsandMarkets strategic analysis services are limited publications containing valuable market information provided to
a select group of customers in response to orders. Our customers acknowledge, when ordering, that MarketsandMarkets
strategic analysis services are for our customers’ internal use and not for general publication or disclosure to third parties.
Quantitative market information is based primarily on interviews and therefore, is subject to fluctuation.
MarketsandMarkets does not endorse any vendor, product or service depicted in its research publications. MarketsandMarkets
strategic analysis publications consist of the opinions of MarketsandMarkets’ research and should not be construed
as statements of fact. MarketsandMarkets disclaims all warranties, expressed or implied, with respect to this research, including
any warranties of merchantability or fitness for a particular purpose.
MarketsandMarkets takes no responsibility for any incorrect information supplied to us by manufacturers or users.
All trademarks, copyrights and other forms of intellectual property belong to their respective owners and may be protected
by copyright. Under no circumstance may any of these be reproduced in any form without the prior written agreement of
their owner.
No part of this strategic analysis service may be given, lent, resold or disclosed to non-customers without written permission.
Reproduction and/or transmission in any form and by any means including photocopying, mechanical, electronic, recording
or otherwise, without the permission of the publisher is prohibited.
For information regarding permission, contact:

1-888-600-6441
sales@marketsandmarkets.com

Brochure - Continuous Renal Replacement Therapy (CRRT) Market

Uploaded by

Document Information

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Brochure - Continuous Renal Replacement Therapy (CRRT) Market

Uploaded by

Copyright:

Available Formats

HEALTHCARE

Global Forecast to 2020

REPORT CODE CONTINUOUS RENAL REPLACEMENT THERAPY (CRRT) MARKET -

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 MARKET SCOPE

1.3.1 MARKETS COVERED

• Global CRRT Market, by Region

1.3.2 YEARS CONSIDERED FOR THE STUDY

2.1 RESEARCH METHODOLOGY STEPS

• FIGURE 1 GLOBAL CRRT MARKET: RESEARCH METHODOLOGY STEPS

2.2 SECONDARY AND PRIMARY RESEARCH METHODOLOGY

2.2.1 SECONDARY RESEARCH

2.2.1.1 KEY DATA FROM SECONDARY SOURCES

• The following non-exclusive list of secondary sources was referred to:

2.2.2 PRIMARY RESEARCH

• FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION

2.2.2.1 KEY DATA FROM PRIMARY SOURCES

2.2.2.2 KEY INDUSTRY INSIGHTS

• FIGURE 3 SUPPLY SIDE

Marketing Director, Leading CRRT company

Senior Scientist, R&D, Leading CRRT Company

• FIGURE 4 DEMAND SIDE

Independent Renal Consultant

2.3 MARKET SIZE ESTIMATION METHODOLOGY

• FIGURE 5 ESTIMATION OF CRRT PROCEDURAL VOLUME

incidence & prevalence data reported by governments/public organizations

• FIGURE 6 RESEARCH METHODOLOGY: TOP-DOWN APPROACH {FOR MARKET SIZE ESTIMATION OF

• FIGURE 7 RESEARCH METHODOLOGY: TOP-DOWN APPROACH (FOR MARKET-SIZE ESTIMATION

• FIGURE 8 RESEARCH METHODOLOGY: BOTTOM-UP APPROACH

• FIGURE 9 RESEARCH DESIGN

2.4 MARKET DATA VALIDATION AND TRIANGULATION

• FIGURE 10 DATA TRIANGULATION STEPS (TOP-DOWN AND BOTTOM-UP APPROACHES)

• FIGURE 11 DATA TRIANGULATION METHODOLOGY

2.5 ASSUMPTIONS FOR THE STUDY

• 1.2 MARKET DEFINITION.......................................................................................................................................................16

• 1.3 MARKET SCOPE...............................................................................................................................................................16

• 1.3.1 MARKETS COVERED......................................................................................................................................17

• 1.3.2 YEARS CONSIDERED FOR THE STUDY.........................................................................................................18

• 2.2 SECONDARY AND PRIMARY RESEARCH METHODOLOGY.............................................................................................21

• 2.2.1 SECONDARY RESEARCH...............................................................................................................................21

• 2.2.1.1 KEY DATA FROM SECONDARY SOURCES................................................................................21

• 2.2.2 PRIMARY RESEARCH....................................................................................................................................22

• 2.2.2.1 KEY DATA FROM PRIMARY SOURCES.....................................................................................23

• 2.2.2.2 KEY INDUSTRY INSIGHTS........................................................................................................24

• 2.3 MARKET SIZE ESTIMATION METHODOLOGY..................................................................................................................26

• 2.4 MARKET DATA VALIDATION AND TRIANGULATION........................................................................................................29

• 2.5 ASSUMPTIONS FOR THE STUDY....................................................................................................................................31

• 4.2 MARKET OPPORTUNITY..................................................................................................................................................38

• 4.3 CRRT MARKET, BY PRODUCT AND MODALITY (2015 VS. 2020)....................................................................................38

• 4.4 CRRT MARKET, BY MODALITY (2015).............................................................................................................................39

• 4.5 CRRT MARKET, BY COUNTRY (2015 VS. 2020)...............................................................................................................40

• 5.2 MARKET SEGMENTATION................................................................................................................................................42

• 5.3 MARKET DYNAMICS........................................................................................................................................................43

• 5.3.1.1 INCREASING PREVALENCE OF AKI..........................................................................................44

• 5.3.1.2 RISING ADOPTION OF CRRT FOR THE TREATMENT OF RENAL DISORDERS..........................44

• 5.3.1.3 GROWING NUMBER OF ICU PATIENTS....................................................................................45

• 5.3.1.4 RAPID RISE IN AGING POPULATION........................................................................................45

• 5.3.1.5 CLINICAL ADVANTAGES OF CRRT OVER INTERMITTENT BLOOD PURIFICATION

• 5.3.1.6 CRRT IS A GOLD STANDARD FOR TREATMENT OF HEMODYNAMICALLY UNSTABLE

• 5.3.1.7 TECHNOLOGICAL ADVANCEMENTS AND NEW PRODUCT LAUNCHES..................................46

• 5.3.1.8 INCREASING PREVALENCE OF SEPSIS....................................................................................47

• 5.3.2.1.1 LACK OF STANDARD TREATMENT GUIDELINES...............................................48

• 5.3.2.1.2 COMPLICATIONS ASSOCIATED WITH CRRT.....................................................49